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Under normal conditions, tau is a highly soluble and na-
tively unfolded microtubule-associated protein (Weingarten 
et al., 1975; Witman et al., 1976). However, there are several 
neurodegenerative diseases known as tauopathies, including 
progressive supranuclear palsy, corticobasal degeneration, cer-
tain forms of frontotemporal dementia, chronic traumatic 
encephalopathy, and Alzheimer’s disease, in which hyperphos-
phorylated, insoluble tau accumulates inside of neurons and 
glia cells (Lee et al., 2001; Jeganathan et al., 2008). Interest-
ingly, evidence suggests that accumulation of tau correlates 
with brain atrophy and clinical symptoms in Alzheimer’s 
disease patients and other tauopathies (Nelson et al., 2012; 
Brier et al., 2016; Johnson et al., 2016). Several studies have 
illustrated that tau pathology appears to propagate from cell 
to cell in a prion-like fashion by an as-yet-unknown mecha-
nism. Some data suggest that pathological tau escapes extra-
cellularly, thereby entering neighboring cells transsynaptically 
(de Calignon et al., 2012; Lasagna-Reeves et al., 2012; Ahmed 
et al., 2014; Yamada et al., 2014; Clavaguera et al., 2015). If 
extracellular pathological tau mediates cell to cell spreading, 
tau binding agents that can access extracellular tau, such as 
anti-tau antibodies, might be a valuable tool to prevent uptake 
of extracellular tau into neurons or other cells to decrease 
spread of tau pathology. Recently, it has been shown that pas-
sive immunization with different anti-tau antibodies can have 
beneficial effects on tau pathology (Boutajangout et al., 2011; 
Chai et al., 2011; d’Abramo et al., 2013; Castillo-Carranza et 
al., 2015; Sankaranarayanan et al., 2015).
In line with this, we have previously developed an anti-
body that blocks cellular tau seeding activity very efficiently 
(Yanamandra et al., 2013; Holmes et al., 2014). Passive immu-
nization with this anti-tau antibody, HJ8.5, decreased overall 
tau accumulation and slowed progression of the disease in a 
human P301S tau–expressing transgenic (P301S-tg) mouse 
model (Yanamandra et al., 2013, 2015). Although these re-
sults demonstrated the neuroprotective effects of a specific 
anti-tau immunotherapy, the mechanisms by which this and 
other anti-tau antibodies prevent pathological tau accumu-
lation remain unknown. Further, treatment of brain diseases 
with antibodies remains a challenge in humans because only 
a small percentage of antibodies in the plasma are able to cross 
the blood–brain barrier (Yanamandra et al., 2015). Therefore, 
we set off to focus on understanding the mechanism by which 
that anti-tau antibody HJ8.5 acts, to determine whether we 
could improve brain delivery and, importantly, investigate the 
requirement of the Fc domain of the HJ8.5 antibody in de-
creasing tau pathology. The latter requirement was assessed 
by using single-chain variable fragments (scFvs) in a gene 
therapy approach targeting the central nervous system (CNS). 
ScFvs, which consist of the variable region of the heavy and 
the light chain connected by different peptide linkers, have 
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been shown to retain their antigen-binding specificity and, 
because of their small size, yield good tissue penetration and 
can be easily packed into an adeno-associated virus (AAV) for 
therapeutic delivery in the CNS (Ahmad et al., 2012).
To date, very little is known about the role of FcγRs on 
microglia in the neuroprotective effects of anti-tau immu-
notherapy. These protective effects could result either from 
sequestration of extracellular tau blocking cellular entrance 
and/or signaling or from IgG binding to FcγRs expressed 
on microglia that facilitate extracellular tau clearance. How-
ever, the latter may also result in a proinflammatory response 
and the development of adverse effects that potentially ex-
acerbate the degenerative process (Lee et al., 2016) or even 
an increase in tau seeding and spreading (Asai et al., 2015). 
A major safety concern from early immunotherapies tar-
geting Aβ was the development of vascular side effects that 
led to the discontinuation of an early clinical trial and have 
continued to be seen with some anti-Aβ antibodies (Senior, 
2002; Nicoll et al., 2003; Orgogozo et al., 2003; Sevigny et 
al., 2016). Subsequently, histopathological studies implicated 
activation of FcγRs on microglia after immunotherapy in 
the development of these adverse effects (Adolfsson et al., 
2012; Freeman et al., 2012).
Here, we show that anti-tau scFvs can be efficiently 
delivered to the brain by AAV2/8-mediated gene transfer, 
where they are predominantly expressed by neurons and as-
trocytes. The scFvs retained their antigen-binding specificity, 
and their expression led to a marked decrease of pathological 
tau accumulation in the hippocampus of P301S-tg mice. De-
pending on the linker used, we were able to detect secreted 
scFvs in the picomolar to low-nanomolar range in the cere-
brospinal fluid (CSF). Interestingly, despite their effects on tau 
pathology, they did not affect absolute human tau (htau) levels 
in the CSF. Our studies provide a strategy for generating im-
munotherapeutics with an improved efficacy that potentially 
limits a proinflammatory response that may be detrimental.
RESULTS AND DISCUSSION
Length of the linker defines binding 
properties of anti–htau scFvs
Work over the past decades has shown that scFvs with the 
orientation VL-linker-VH show a greater binding capacity 
than VH-linker-VL constructs. Furthermore, the length of 
the linker influences not only efficient folding and solubility 
but also affinity of the scFvs (Desplancq et al., 1994; Sheik-
holvaezin et al., 2006). Based on these studies, we designed 
three anti-tau scFvs that differ only in the length of the gly-
cine-based peptide linker that connects the variable region 
of the light (VL) and the heavy chain (VH). A secretory signal 
peptide was added at the N terminus and a hemagglutinin 
(HA) tag at the C terminus to facilitate detection (Fig. 1 A). 
First, we confirmed expression and secretion of all three scFvs 
(SC1, SC2, and SC3 scFv) in vitro. HEK293T cells were 
transfected with the scFv constructs, and their presence was 
confirmed in cell lysates as well as culture supernatants by im-
munoblot analysis (Fig. 1 B, bottom). To determine whether 
they retained their ability to bind to tau, the culture super-
natant was mixed with recombinant htau, and coimmuno-
precipitation was performed. Immunoblot analysis confirmed 
binding of the scFvs to htau (Fig. 1 B, top). To determine the 
specificity of anti-tau scFvs, brain lysates from P301S-tg mice 
and nontransgenic controls were subjected to immunoblot-
ting analysis using purified scFvs. Notably, immunoblotting 
for htau revealed that all three scFvs effectively immunore-
acted with htau and not mouse tau (Fig. 1 C). Additionally, 
surface plasmon resonance (SPR) measurements with immo-
bilized htau revealed varying binding constants (KD) for all 
three scFvs, with SC1 scFv displaying the lowest and SC2 
scFv the highest KD (Fig.  1 D). Collectively, these analyses 
validated that our anti-tau scFvs retain biological activity that 
is specific for htau, with different binding affinities.
Functional anti-tau scFvs can be expressed in the brain  
in vivo by AAV-mediated gene transfer
Based on our SPR data (Fig. 1 D), we decided to test the scFv 
with the slowest dissociation rate (SC1 scFv) and that with 
the fastest association rate (SC3 scFv) in vivo. Therefore, the 
scFvs were packaged into AAV2/8 and delivered at postnatal 
day 0 (P0) by bilateral intracerebroventricular (ICV) injec-
tions. Immunohistological staining with an anti-HA antibody 
revealed widespread expression of the scFvs throughout the 
brain at 3 mo after injection (Fig. 2 A). In line with a previous 
study (Chakrabarty et al., 2013), costaining with a neuronal 
(NeuN; Fig. 2 B), astrocytic (GFAP; Fig. 2 C), or microglial 
(Iba1; Fig. 2 D) marker revealed expression mostly in neurons 
and astrocytes, but rarely microglia. Furthermore, coimmu-
noprecipitation from brain lysates of AAV-injected P301S-tg 
mice showed that the scFvs retain their biological activity to 
bind htau (Fig. 2 E). In addition to expression in the brain, 
we detected scFvs in liver, heart, lung, and muscle samples 
of these mice (Fig. 2 F), showing that the AAV expression is 
not restricted to the brain despite ICV injections. However, 
we did not observe any gross changes in tissue morphology 
in 16-wk-old mice as assessed by hematoxylin and eosin 
staining (not depicted). Furthermore, immunoblot analysis 
failed to detect any scFvs in plasma samples (Fig. 2, G and H), 
most likely because of the short half-life of scFvs in plasma. 
Thus, AAVs can be used to express scFvs in the brain while 
retaining scFv function.
SC1 and SC3 scFvs affect soluble tau levels  
and decrease p-tau staining in specific hippocampal 
regions in aged P301S-tg mice
After validating expression of the scFvs and confirming their 
binding capabilities to htau, we aged AAV2/8 scFv-injected 
P301S-tg mice to 9 mo to investigate effects on tau pathology. 
P301S-tg mice begin to develop tau pathology at 5–6 mo, 
and it is robust by 9 mo of age. As a control, we injected mice 
with an AAV2/8 expressing an scFv with no binding affinity 
for any mouse protein. Immunoblot analysis of brain lysates 
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Figure 1. Length of the linker defines binding properties of anti–htau-scFvs. (A) Graphical representation of the three scFvs used. VL, variable region 
of the light chain; VH, variable region of the heavy chain; SP, secretory signal peptide; HA, HA-epitope tag. (B) Coimmunoprecipitation (IP) with an anti-HA 
antibody after mixing cell culture supernatants of scFv-transfected HEK 293T cells with recombinant (rec.) human P301S tau shows coprecipitation of 
human P301S tau with all scFv variants when analyzed by immunoblot (n = 3). (C) Immunoblot analysis of brain lysates from WT and P301S-tg mice as well 
as recombinant human P301S and mouse WT tau with scFvs used as a primary antibody shows specificity of the scFvs to htau with no detection of mtau (n 
= 3). (D) SPR measurements were performed after binding of htau to the surface and floating purified scFvs in the flow cell. Association rate (Ka), dissociation 
rate (Kd), and binding constant (KD) are different for all scFv variants. RU, relative units. Values for full-length HJ8.5 in the table in D are from the original 
publication (Yanamandra et al., 2013). Results are representative for three independent experiments for B and C and one experiment for D.
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Figure 2. Functional anti-tau scFvs can be expressed in the brain in vivo by AAV-mediated gene transfer. (A) Immunohistochemical staining 
(anti-HA) of brain sections from a mouse that received an ICV injection of AAV2/8 SC3 scFv at P0 and was analyzed 3 mo later. The scFvs showed good 
expression throughout the brain (n = 6). Bar, 1 mm. (B–D) Immunofluorescence staining of brain sections from AAV2/8 scFv–injected mice with an HA anti-
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confirmed expression of the scFvs in all aged mice used in 
this study (Fig. S1, A–C). At 9 mo of age, control scFv–treated 
mice displayed a substantial amount of abnormally phosphor-
ylated htau (p-tau) in the hippocampus (stained by AT8, de-
tecting paired helical filament tau phosphorylated at Ser202 
and Thr205). Treatment with either SC1 or SC3 scFv revealed 
a nonsignificant trend toward lowering the levels of p-tau in 
assessing the entire hippocampus (Fig. 3, A and B). However, 
when assessing specific hippocampal subregions, there was 
significantly lower p-tau staining in SC1 scFv–treated mice in 
the CA1 cell body region (Fig. 3 C) as well as the CA1 stra-
tum radiatum (Fig. 3 D) compared with control scFv–treated 
mice. Because of high variability, the effect did not quite reach 
statistical significance for SC3 scFv–treated mice in either re-
gion (Fig. 3, C and D). To determine soluble and insoluble 
htau levels, we performed sequential biochemical extractions. 
Hippocampus samples were first extracted in a high salt 
buffer (RAB buffer), before the remaining pellet was resus-
pended in a detergent-containing buffer (RIPA). The final 
pellet containing highly insoluble tau species was solubilized 
in a 70% formic acid (FA) solution. ELI SA measurements re-
vealed significantly higher levels of RAB-soluble htau in SC1 
scFv–treated mice and the same nonsignificant trend for SC3 
scFv–treated mice (Fig. 3 E). This finding was accompanied 
by a strong and significant decrease in htau in RIPA fractions 
after both treatments (Fig. 3 F). Expression of either scFv did 
not affect FA-soluble tau levels (Fig. 3 G). Next, we looked 
at levels of scFvs in RAB fractions and detected similar levels 
of SC1 and SC3 scFvs (Fig. S1 D). To validate binding of 
the scFvs to htau, we performed tau-scFv complex–specific 
ELI SAs. These analyses demonstrated that both SC1 and SC3 
scFvs are detectable in a complex with htau in hippocam-
pal RAB fractions (Fig. S1 E). Interestingly, further analysis 
revealed a negative correlation for RAB-soluble htau levels 
with AT8 staining in the hippocampus (Fig. S2 A), whereas 
there was no correlation for RIPA-soluble htau (Fig. S2 B) 
and there was a positive correlation for insoluble htau levels 
(Fig. S2 C). Collectively, SC1 and SC3 scFvs decrease tau pa-
thology as seen by p-tau staining, whereas total htau appears 
to be shifted from RIPA-soluble to RAB-soluble fractions.
SC1 and SC3 scFvs are detectable in CSF but do not 
significantly alter tau levels
Because we hypothesized a role for extracellular tau in the 
progression of tau pathology, we set out to determine a poten-
tial effect of the scFvs on the levels of extracellular tau. htau 
levels in CSF decrease over time in P301S-tg mice. Therefore, 
we wanted to look at time-dependent differences. First, we 
collected CSF from young (3–4.5 mo old) P301S-tg mice 
and analyzed levels of secreted scFvs by an indirect ELI SA. 
Here, SC1 and SC3 scFvs were detectable in CSF samples of 
all mice, with SC3 scFv displaying a ∼40× higher level than 
SC1 scFv (∼263 pM for SC1 scFv vs. ∼10 nM for SC3 scFv; 
Fig. 4 A). Because similar levels of SC1 and SC3 scFvs are 
present in brain tissue (Fig. S1, D and E), this suggests a longer 
extracellular half-life of SC3 scFv. Analysis of htau levels in the 
CSF by an ELI SA using a Simoa HD analyzer showed no sig-
nificant differences between groups despite a trend to lower 
htau levels in SC3 scFv–treated mice (Fig. 4 B). In addition, 
we collected interstitial fluid (ISF) from the same mice by in 
vivo brain microdialysis and assessed htau levels by ELI SA. In-
terestingly, we observed the same trend toward lowering htau 
in the ISF of SC3 scFv–treated mice (Fig. S3 A). htau levels 
in ISF and CSF correlated well when SC1 scFv– and SC3 
scFv–treated mice were analyzed (Fig. S3 B) but showed no 
correlation in control scFv–treated mice (Fig. S3 C), pointing 
to a potentially different clearance mechanism for htau in the 
presence of either SC1 or SC3 scFv. To confirm binding of 
the scFvs to extracellular tau, we performed coimmunopre-
cipitation experiments from ISF samples. Immunoblot analy-
sis confirmed binding of the scFvs to tau (Fig. S3 D).
In CSF samples of aged (9 mo old) P301S-tg mice, we 
found a difference in the levels of SC1 and SC3 scFvs (Fig. 4 C) 
similar to that seen in young mice (∼116 pM for SC1 scFv 
vs. ∼4 nM for SC3 scFv; Fig. 4 C). Analysis of htau levels in 
the CSF showed no significant differences between groups 
despite a trend to lower htau levels in both SC1 scFv– and SC3 
scFv–treated mice (Fig. 4 D). Of note is that the concentration 
of htau in CSF of the young P301S-tg mice was ∼20 pM or 
10× lower than the concentration of SC1. In addition to pos-
sible effects on clearance, binding of scFvs to extracellular tau 
could potentially influence pathology by preventing tau uptake 
into neurons. To test this idea, we treated neuroblastoma cells 
(N2a cells) and primary cortical neuronal cultures with fluo-
rescently labeled tau in the presence and absence of scFvs and 
analyzed uptake by flow cytometry. Interestingly, both scFvs 
were able to decrease tau uptake into both cell types (Fig. S3, 
E and F). Furthermore, we determined the effect of the scFvs 
on seeding activity by using biosensor cells, which express a 
repeat-domain tau-YFP and -CFP construct. Seeding can be 
body revealed expression of scFvs by neurons (B; NeuN) and astrocytes (C; GFAP), but rarely microglia (D; Iba1). n = 5 for each costaining; images represent 
maximum-intensity projections of z-stacks. Bars: (overview) 50 µm; (magnification) 10 µm. (E) Immunoblot analysis of cortex lysates (bottom) from mice 
injected with either AAV2/8 SC1 scFv or AAV2/8 SC3 scFv showed expression of the scFvs in all analyzed mice. Immunoprecipitation (IP) experiments (top) 
with an HA antibody showed coprecipitation of htau from mice that expressed the human P301S tau transgene, but not WT mice. Immunoblot is repre-
sentative of two independent experiments that were performed with at least three P301S-tg mice per group. (F) Immunoblot analysis of different organs 
showed expression of scFvs in liver, heart, lung, and muscle lysates of mice 2.5 mo after ICV injection of AAV2/8 scFvs. Immunoblot is representative of eight 
independent experiments (n = 4 for SC1 scFv and SC3 scFv, respectively). (G and H) SC1 and SC3 scFvs were undetectable by immunoblot analysis of plasma 
samples from mice 2.5 mo after ICV injection of AAV2/8 scFvs (n = 6 for SC1 scFv and n = 7 for SC3 scFv).
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induced by applying extracellular tau, which can then be quan-
tified by measuring the fluorescence resonance energy transfer 
(FRET) signal by flow cytometry (Holmes et al., 2014). To test 
whether the scFvs can inhibit seeding, we immunodepleted 
tau from brain lysates of P301S-tg mice with the scFvs and 
applied those samples to the biosensor cells. Quantification of 
the resulting FRET signal revealed a significant decrease in 
seeding activity in the immunodepleted lysates compared with 
control-treated samples (Fig. S3 G). Thus, SC1 and SC3 scFvs 
are efficiently secreted but, despite substantial levels in the CSF, 
do not significantly affect overall total htau levels in the CSF 
or ISF but could potentially inhibit tau uptake and seeding.
Concluding remarks
In conclusion, we demonstrate that the length of the linker 
influences binding properties of scFvs to htau. ICV injection 
Figure 3. SC1 and SC3 scFvs affect soluble tau levels and decrease p-tau staining in specific hippocampal regions in aged P301S-tg mice. 
(A) Hippocampus of AAV2/8 scFv-injected mice after immunohistochemical staining with anti-AT8, a phospho-tau antibody. Images are representative of 
animals stained in one histochemical experiment (n = 17 for control scFv, n = 13 for SC1 scFv, and n = 16 for SC3 scFv). Arrow, CA1 cell body layer; arrow-
head, stratum radiatum. Bars, 500 µm. (B) Quantification of percentage of area covered by AT8 showed a nonsignificant trend to lower phospho-tau in the 
full hippocampus (P = 0.25 by one-way ANO VA). (C and D) Quantification of percentage of area covered by AT8 showed significantly lower phospho-tau 
levels in CA1 cell bodies (C; *, P = 0.02 by one-way ANO VA) and the stratum radiatum (D; *, P = 0.04 by one-way ANO VA) in SC1 scFv–treated mice and 
nonsignificant trends for SC3 scFv–treated mice. (E–G) htau-specific ELI SAs revealed significantly increased RAB-soluble tau in the hippocampus of SC1 
scFv–treated mice (E; **, P = 0.006 by one-way ANO VA), decreased levels of RIPA-soluble tau in SC1 scFv– and SC3 scFv–treated mice (F; ***, P = 0.0002 by 
one-way ANO VA), and no difference in FA-soluble (G; P = 0.67 by one-way ANO VA) tau levels (n = 17 for control scFv, n = 14 for SC1 scFv, and n = 16 for 
SC3 scFv). (B–G) All graphs are means ± SEM and were analyzed by one-way ANO VA, followed by Dunnett’s multiple comparison post hoc test comparing 
every column to control scFv: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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of AAV2/8 scFvs at P0 led to widespread expression of the 
constructs throughout the brain, where they retained their 
antigen-binding capability and bound tau in the brain in 
vivo. Furthermore, expression of the scFvs strongly reduced 
p-tau and detergent-soluble tau accumulation in P301S-tg 
mouse hippocampus. Finally, we confirmed secretion of scFvs 
into the extracellular space, but intriguingly did not detect 
significantly altered total extracellular tau levels despite ev-
idence of scFvs binding to extracellular tau and effects of 
scFvs on tau pathology.
Collectively, these results suggest that microglial- 
mediated tau clearance is likely not mandatory in the mech-
anism by which anti-tau antibodies are protective against tau 
accumulation. To our knowledge, this is the first study to re-
port effects of scFv’s targeting of tau to reduce tau pathology. 
One recent study found that p-tau staining was reduced after 
peripheral administration with a full-length anti–phospho-tau 
antibody with an effectorless Fc region mutation (Lee et al., 
2016). The mechanism of the effect was not clear, as assess-
ment of binding to tau in vivo or biochemical tau levels was 
not performed. Sankaranarayanan et al. (2015) recently re-
ported reduced CSF tau levels after peripheral treatment with 
a full-length anti–phospho-tau antibody. These results are dif-
ficult to compare to our study because of major differences 
in study design. Although their group used a full-length an-
tibody to treat rTg4510 transgenic mice, which show higher 
CSF tau levels in general, we used scFvs to treat P301S-tg 
mice. Although we did not observe an effect on total CSF 
tau after expression of the scFvs, we did observe binding of 
the scFvs to tau in the brain and ISF. This suggests that the 
clearance of a tau-scFv complex is likely to take on the clear-
ance pathway of the secreted scFvs. Such binding may not 
alter total tau levels if the half-life of scFv-tau complexes is 
similar to that of unbound tau. However, such binding could 
alter clearance pathways of the scFv-tau complex. Clearance 
of scFv-tau complexes from the brain is likely to involve the 
brain’s glymphatic system and lymphatics into CSF, neck 
lymph nodes, and blood as opposed to local clearance by mi-
croglia. We did observe a positive correlation between CSF 
htau and ISF tau, which is seen only in scFv-treated but not 
control mice. This suggests that anti-tau scFv–mediated clear-
ance mechanisms act in concert with blocking tau uptake, 
seeding, and possibly signaling, the detailed mechanism of 
which can be addressed in future studies.
With regard to the development of therapeutics for 
tauopathies, this study could have several important implica-
tions. First, scFvs have the advantage of more efficient brain 
diffusion over full-length antibodies in passive immunother-
apy after CNS gene transfer or direct CNS infusion (Huang 
et al., 2013). Second, scFvs can be cost-efficiently produced in 
Figure 4. SC1 and SC3 scFvs are detectable 
in CSF but do not significantly alter tau lev-
els. (A) Analysis of CSF from young (3–4.5 mo old) 
P301S-tg mice by ELI SA revealed levels of SC1 
scFvs in the low-nanomolar range (7.7 ± 2.5 ng/
ml; ∼263 pM) and high levels (313 ± 39.2 ng/ml; 
∼10 nM) of SC3 scFvs (n = 7 for SC1 scFv and n 
= 11 for SC3 scFv). (B) Analysis of htau levels in 
CSF samples of young P301S-tg mice by using a 
homebrew Simoa assay showed no significant dif-
ference between groups (n = 8 for control scFv, n = 
6 for SC1 scFv, and n = 10 for SC3 scFv; P = 0.20 by 
one-way ANO VA). (C) ELI SA measurements of scFv 
levels in CSF samples of 9-mo-old P301S-tg mice 
showed similar differences in scFv levels between 
SC1 scFv– and SC3 scFv–treated mice as seen in 
young mice (3.4 ± 0.5 ng/ml [∼116 pM] for SC1 
scFv and 118.7 ± 17.4 ng/ml [∼4 nM] for SC3 scFv; 
n = 12 for SC1 scFv and n = 16 for SC3 scFv). (D) 
Analysis of htau levels in CSF samples of 9-mo-old 
P301S-tg mice by using a homebrew Simoa assay 
showed no significant difference between groups 
(n = 17 for control scFv, n = 12 for SC1 scFv, and 
n = 15 for SC3 scFv; P = 0.51 by one-way ANO VA). 
(A–D) All graphs represent means ± SEM.
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bacteria (Ahmad et al., 2012) whereas full-length antibodies 
usually have to be expressed and purified from mammalian 
cells. Third, lack of the Fc domain in scFvs reduces poten-
tial immunogenicity (Huang et al., 2013; Lee et al., 2016), 
thereby reducing the risk of inflammation-related side effects. 
Fourth, AAV-mediated gene transfer for therapeutic delivery 
could potentially be a feasible method for therapeutic de-
livery of scFvs. Interestingly, AAV-mediated gene transfer to 
the CNS is already being used successfully in clinical trials to 
treat several other diseases (Kantor et al., 2014). Combining 
this approach with the less immunogenic scFvs—which are 
already tested as therapeutic agents in clinical trials for other 
diseases (Ahmad et al., 2012)—might be a valuable tool in 
future therapeutic applications for brain disorders in general 
and tauopathies in particular.
MATERIALS AND METHODS
Animal procedures and sample collection
P301S tau transgenic mice (line PS19, purchased from The 
Jackson Laboratory) express the P301S human T34 isoform 
(1N4R) under control of the prion protein promoter. These 
mice are on a B6C3 background and were generated and 
characterized previously (Yoshiyama et al., 2007). Animal 
procedures were performed according to protocols approved 
by the Animal Studies Committee at Washington University 
School of Medicine. For AAV expression, pups received a bi-
lateral ICV injection on P0 of 2  µl AAV (2.5 × 1013 vg/
ml). Because of the reported high variability in tau pathology 
between aged male and female P301S-tg mice (Zhang et al., 
2012; Yanamandra et al., 2013), we used only males for the 
study in which mice were aged to 9 mo, but mixed genders 
whenever young (3–4.5 mo old) mice were used. At time 
of death, mice were anesthetized and CSF was collected as 
described previously (DeMattos et al., 2002). Blood samples 
were collected in EDTA-treated tubes before cardiac perfu-
sion with PBS/heparin. Blood samples were spun down (10 
min, 2,000 g, 4°C), and blood plasma was collected. Brains 
were taken out, one hemisphere dissected and the other 
hemisphere immersion fixed in 4% paraformaldehyde. After 
24 h, paraformaldehyde was exchanged with 30% sucrose and 
the brain was incubated for 48 h in this solution before it was 
frozen with 2-methylbutane on dry ice. Frozen brains were 
kept at −80°C before they were sectioned on a microtome 
(50-µm thickness). Floating sections were kept in 24-well 
plates with 30% ethylene glycol, 15% sucrose, and 0.2 M so-
dium phosphate at −20°C.
Antibodies
Biotinylated and unbiotinylated anti-HJ8.5 (htau-specific 
antibody; Yanamandra et al., 2013), anti HJ8.7 (detects htau 
and mouse tau [mtau]; Yanamandra et al., 2013), and an-
ti-Tau5 (htau specific; Yanamandra et al., 2013) were used. 
Anti-NeuN and anti-GFAP were purchased from EMD Mil-
lipore, and anti-Iba1 was from Wako Pure Chemical Indus-
tries. Biotinylated and unbiotinylated anti–htau (clone HT7), 
biotinylated phospho-htau (clone AT8), and fluorescently la-
beled secondary antibodies were obtained from Invitrogen. 
Biotinylated peroxidase-coupled secondary antibodies were 
from Jackson ImmunoResearch Laboratories, Inc., and flu-
orescently labeled streptavidin was from Molecular Probes. 
Biotinylated anti-HA was purchased from Vector Laborato-
ries and Bethyl Laboratories, Inc., and peroxidase-coupled 
anti-HA was from Roche. Anti-HA agarose beads and an-
ti-actin were obtained from Sigma-Aldrich.
Biochemical extraction of different tau species
Frozen brain pieces were weighed, and 30  µl RAB buf-
fer per mg of tissue added (RAB buffer = 0.75  M NaCl, 
0.1 M MES, 1 mM EGTA, 0.5 mM MgSO4, 2 mM DTT, 
and 1  mM Na3VO4, pH 6.8). Samples were sonicated on 
ice for 1 min (FB120; Thermo Fisher Scientific; 30% am-
plitude, 1-s intervals) before spinning them at 50,000 g (20 
min, 4°C). The supernatant was collected (RAB fraction, 
contains salt-soluble tau) before adding RIPA buffer (0.15 M 
NaCl, 50 mM Tris, 25 mM EDTA, 1% Triton X-100, 0.5% 
sodium deoxycholate, and 0.5% SDS, pH 8.0) at 30 µl/mg 
tissue (RIPA buffer = 0.15 M NaCl, 50 mM Tris, 25 mM 
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and 
0.5% SDS, pH 8.0). After another round of sonication, sam-
ples were centrifuged at 50,000 g (20 min, 4°C). Supernatant 
was collected (RIPA fraction, contains detergent-soluble tau), 
and 10 µl of 70% FA solution per mg of tissue was added. 
Sonication and centrifugation and collection of supernatant 
(FA fraction, contains insoluble tau) were repeated. RAB and 
RIPA buffers were supplemented with 1× PhosSTOP and 
1× cOmplete (Roche). All samples were stored at −80°C; 
before performing ELI SA assays, FA fractions were neutral-
ized with 1 M Tris, pH 11.
Coimmunoprecipitation
HEK293T cells were transiently transfected with Lipofect-
amine 2000. 48 h after transfection, supernatant was collected. 
After centrifugation at 1,500 g (5 min, room temperature), a 
small aliquot of each supernatant fluid was preserved and di-
luted with immunoblot sample buffer for immunoblot anal-
ysis (i.e., supernatant). The remaining supernatant was mixed 
with 10 µl anti-HA agarose beads (Sigma-Aldrich) and 1 µg 
recombinant human P301S tau. For coimmunoprecipitation 
from brain lysates, cortex pieces were homogenized in a mod-
ified RIPA buffer (50 mmol/L Tris-HCl, pH 7.4, 1% NP-40, 
0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L 
EDTA, and protease inhibitors) and incubated on ice for 15 
min. After centrifugation at 20,000 g (15 min, 4°C), a small 
aliquot of each supernatant fluid was preserved and diluted 
with immunoblot sample buffer for immunoblot analysis (i.e., 
lysate). Protein concentration was determined by BCA assay, 
and 100 µg protein lysate was mixed with 10 µl anti-HA aga-
rose beads in modified RIPA buffer.
After incubation for 1 h at room temperature, the aga-
rose beads were washed extensively with PBS, and bound 
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proteins were eluted by boiling the beads in immunoblot 
sample buffer (i.e., HA-IP).
For coimmunoprecipitation from ISF, samples were col-
lected by in vivo brain microdialysis from SC3 scFv–injected 
mice. SC3 scFv concentrations were determined by ELI SA, 
and a sample volume containing ∼800 pg SC3 scFv was used 
for the IPs. As a control, ISF sample buffer was mixed with 
purified SC3 scFvs at the same concentration. 5 µg anti-tau 
antibody (HJ8.7) was added to each tube, and the samples 
were incubated for 2 h on a rotator at 4°C. After addition of 
20 µl protein G Sepharose beads (GE Healthcare), the tubes 
were rotated at 4°C for another 2 h. Beads were washed once 
with cold PBS before bound proteins were eluted by boiling 
the beads in immunoblot sample buffer (i.e., tau-IP). Pro-
teins were resolved by NuPAGE Novex 4–12% Bis-Tris gels 
(Thermo Fisher Scientific), blotted onto nitrocellulose mem-
branes, and visualized with enhanced chemiluminescence 
after incubation of the blots with the respective antibodies.
ELI SA
To measure unbound scFvs, an indirect ELI SA procedure was 
applied. Half-well 96-well plates were coated overnight at 4°C 
with 50 ng/ml recombinant human WT tau. After extensive 
washes with PBS, the wells were blocked with 4% BSA in 
PBS before diluted samples (sample buffer: 0.25% BSA and 
300 mM Tris, pH 8.0, in PBS with protease inhibitors) were 
incubated overnight at 4°C. After washing, the wells were 
incubated with a biotinylated HA antibody (Bethyl Labora-
tories, Inc.) for 1.5 h. For htau-specific measurements or to 
detect htau–scFv complexes in brain homogenates, a sandwich 
ELI SA was used. Plates were coated with Tau5 antibody and 
blocked with 4% BSA in PBS. Samples were diluted in sample 
buffer and, as a detector antibody, either biotinylated anti–
htau (clone HT7) or biotinylated anti-HA was used. All ELI 
SAs were developed with super-slow TMB substrate solution 
(Sigma-Aldrich) before reading on a plate reader at 650 nm.
Generation and purification of scFvs
HJ8.5 monoclonal antibody was raised by immunizing 
tau-knockout mice with htau as described previously (Yan-
amandra et al., 2013). This antibody recognizes amino acids 
25–30 of the full-length human 1N4R sequence (Yana-
mandra et al., 2013). After sequencing, the variable regions 
were cloned and combined in one plasmid connected by a 
(GGGS)1-linker. A secretory signal peptide was added at the 
N terminus and an HA-tag at the C terminus. The different 
linker sequences were introduced by site-directed mutagen-
esis. For purification, Expi293F cells (Gibco) were grown 
in Expi293 Expression Medium (Gibco) to a density of 106 
cells/ml before they were transiently transfected with Lipo-
fectamine 2000 (Invitrogen). The scFvs were affinity-purified 
from supernatant 4 d later by using a HiTrap Protein L column 
(GE Healthcare) according to the manufacturers’ instructions. 
After elution, the scFvs were dialyzed in PBS and concen-
trated with an Amicon Ultra 10K device (EMD Millipore).
Immunofluorescence
Sections were mounted on gelatin-coated slides and air-dried 
for 30 min. After extensive washing with PBS, sections were 
blocked with 5% normal goat serum in PBS with 0.1% Tri-
ton X-100. After washing, sections were incubated with pri-
mary antibodies diluted in PBS overnight at 4°C followed 
by three more wash steps. Fluorescently labeled secondary 
antibodies or streptavidin were diluted in PBS and applied to 
the sections. After washing, sections were coverslipped with 
Prolong Gold with DAPI (Invitrogen). Images were taken as 
a z-stack (one image every 1.5 µm) with a Nikon A1Rsi with 
a 40× oil immersion objective operated by NIS-Elements 
AR software version 4.30.02 (Nikon). Images were further 
processed with the use of ImageJ/Fiji software version 2.0.0 
(National Institutes of Health) and Photoshop CS6 version 
13.0.1 (Adobe Systems).
Immunohistochemistry
Sections were stained in a free-floating format in a 12-well 
plate. After extensive washing with TBS, sections were blocked 
with 0.3% hydrogen peroxide for 10 min. After washing, sec-
tions were blocked for 30 min in 3% milk in TBS and 0.25% 
Triton X-100 (TBS-X). The respective biotinylated primary 
antibody was diluted in 3% milk in TBS-X, and the sections 
were incubated overnight at 4°C. After washing, sections were 
incubated with ABC solution (VectaStain) according to the 
manufacturer’s instructions, followed by another three wash 
cycles. Sections were developed in DAB solution (Sigma- 
Aldrich), washed, and mounted on slides. After drying over-
night, sections were dehydrated in increasing ethanol con-
centrations followed by xylene. Slides were coverslipped with 
Cytoseal 60 (Thermo Fisher Scientific) and scanned on a 
NanoZoomer 2.0-HT system (Hamamatsu Photonics). Im-
ages were further processed and quantified with the use of Im-
ageJ/Fiji software version 2.0.0. All areas were quantified in at 
least four sections (300 µm apart from each other) per mouse.
In vivo microdialysis
In vivo brain microdialysis was performed as described pre-
viously (Yamada et al., 2014). In brief, bore holes were made 
above the left hippocampus (AP −3.1 mm, ML −2.5 mm, 
DV −1.2 mm). A guide cannula (Eicom Microdialysis) was 
stereotactically inserted in the left hippocampus (12° angle) 
and cemented. After a recovery period and habituation to 
the Raturn sampling caging system (BASi), a 2-mm 1,000-
kD MWCO cutoff AtmosLM microdialysis probe (Eicom) 
connected to a peristaltic push-pull pump (SciPro) was in-
serted through the guide cannula. As a perfusion buffer, 25% 
human albumin solution (Gemini Bio) was diluted to 4% 
with artificial CSF (1.3 mM CaCl2, 1.2 mM MgSO4, 3 mM 
KCl, 0.4  mM KH2PO4, 25  mM NaHCO3, and 122  mM 
NaCl, pH 7.35). ISF samples were collected at a flow rate 
of either 1 or 0.5  µl/min in a refrigerated microsampler 
(Univentor). Analysis by ELI SA was performed at the com-
pletion of each experiment.
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Recombinant AAV production
All scFvs were cloned into the AAV vector under control of 
the chicken β-actin promoter. The rAAV2/8-scFvs used in 
these studies were prepared at the Hope Center Viral Vectors 
Core at Washington University School of Medicine.
Recombinant htau
Recombinant human P301S (1N4R) and WT tau (2N4R) 
were cloned into pRK172 and purified as described pre-
viously (Goedert and Jakes, 1990). Aliquots were frozen at 
−80°C for one-time use. For tau uptake assays, 200 µl of a 
8-µM recombinant human P301S tau solution was incu-
bated with 0.025 mg Alexa Fluor 647 NHS ester (Molecu-
lar Probes) for 1 h at room temperature before the mixture 
was moved to 4°C overnight. Free dye was quenched with 
100 mM glycine before the sample was dialyzed in PBS.
Seeding assay
Seeding with the biosensor cells was performed as described 
previously (Holmes et al., 2014). In brief, htau concentration 
in RAB lysates from P301S-tg mice was measured by ELI 
SA. Lysate containing 7 nM htau was immunodepleted by 
incubation with 700 nM scFvs (100×) and anti-HA beads for 
1 h at 4°C. After a brief centrifugation, the supernatant was 
diluted with PBS and mixed with Lipofectamine 2000 before 
adding it to the biosensor cells in a 96-well plate. Cells were 
incubated for 24 h before the cells were trypsinized, fixed, and 
resuspended in flow buffer (1× HBSS with 1% FBS and 1 mM 
EDTA). The number of cells with a FRET signal was analyzed 
on a MAC SQuant VYB flow cytometer. Data analysis was 
performed with FlowJo Version 10 and analyzed as percentage 
of cells with a FRET signal within the single cell population.
Simoa assays
To measure htau in CSF samples, a Simoa homebrew assay was 
developed. Paramagnetic carboxylated beads (Quanterix) were 
activated with 0.3 mg/ml 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC; Thermo Fisher Scientific) 
and coated with 0.3 mg/ml anti-HJ8.7 (binds to htau and 
mtau) according to the manufacturer’s instructions. For detec-
tion, anti–htau (clone HT7) was biotinylated at a 40× molar 
ratio and used at a final concentration of 0.6 µg/ml with a SBG 
enzyme (Quanterix) concentration of 350 pM. All samples and 
standards were diluted in tau calibrator diluent (Quanterix) and 
run on a Simoa HD-1 analyzer (Quanterix) as a two-step assay.
Statistical analysis
All graphs represent means ± SEM. Statistical analysis was per-
formed with GraphPad Prism 5.01 using one-way ANO VA 
with Dunnett’s post hoc test comparing every group to 
the control-treated group.
SPR
SPR experiments were performed as described previously 
(Yanamandra et al., 2013). In brief, a Biacore sensor chip 
CM-5 was activated in a BIAcore 2000 SPR instrument (GE 
Healthcare-BIAcore) by using a 1:1 ratio of EDC and N-hy-
droxysuccinimide (NHS). Recombinant human WT tau in 
10 mM sodium acetate, pH 3.5, was immobilized on the sen-
sor chip surface with a flow rate of 5 µl/min. The remaining 
unbound area was blocked by 1 M ethanolamine, pH 8.5. For 
reference, one flow cell was activated, followed by blocking 
with 1 M ethanolamine. All scFvs were injected at different 
concentrations (6.25, 12.5, 25, 50, 100, 200, and 400 nM) in 
filtered, degassed 0.01 M Hepes buffer, 0.15 M NaCl, 0.005% 
surfactant P20, pH 7.4, at a flow rate of 10 µl/min. All sam-
ples were run in duplicate. After each run with a single anti-
body concentration, the surface of the chip was regenerated 
by using 10 mM glycine, pH 1.7. Data analysis was performed 
by using BIAevaluation software (GE Healthcare-BIAcore). 
Association (Ka) and dissociation (Kd) were calculated using 
Fit kinetics simultaneous Ka/Kd (global fitting) with a 1:1 
(Langmuir) interaction model.
Tau uptake assay
Undifferentiated neuroblastoma cells (N2a) were split at 
25,000 cells/well in a poly-l-lysine–coated 96-well plate 24 h 
before the start of the experiment. For uptake assays with pri-
mary cortical neurons, neurons were prepared as described 
previously (Beaudoin et al., 2012) and plated at 50,000 cells/
well in a poly-l-lysine–coated 96-well plate. Uptake ex-
periments were performed on 7–9 d in vitro. 20-nM Alexa 
Fluor 647–labeled recombinant human P301S tau (1N4R) 
was mixed with purified scFvs at the indicated concentra-
tions and incubated for 30 min at room temperature in the 
dark. 100 µl of this mix was added to each well (technical 
duplicates or triplicates for each treatment), and cells were 
incubated for 24 h before being trypsinized and resuspended 
in flow buffer (1× HBSS with 1% FBS and 1 mM EDTA). 
The rate of tau uptake was analyzed on a MAC SQuant VYB 
flow cytometer (20,000 cells per well analyzed for N2a cells; 
full well analyzed for primary cortical neurons). Data analysis 
was performed with FlowJo Version 10 and analyzed as rela-
tive fluorescence units.
Online supplemental material
Fig. S1 (A–C) shows immunoblots revealing expression of 
the scFvs in cortex lysates of all 9-mo-old P301S-tg mice 
analyzed in the study; Fig. S1 (D and E) shows that unbound 
scFvs as well as scFv-tau complexes exist in these lysates as 
measured by ELI SA. Fig. S2 depicts correlation analysis be-
tween hippocampal AT8-staining and htau levels in RAB, 
RIPA, and FA fractions, demonstrating a correlation for levels 
of AT8 with total htau levels in RAB and FA fractions, but 
not RIPA fractions. Fig. S3 A shows ELI SA measurements 
of htau levels in ISF with no significant differences between 
control-treated and SC1 scFv– or SC3 scFv–treated mice. Fig. 
S3 (B and C) depicts correlation analysis between htau levels 
in CSF and ISF of young mice, showing a significant cor-
relation in treated but not control mice. Fig. S3 D shows an 
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immunoblot of coprecipitation experiments from ISF sam-
ples, revealing extracellular tau-scFv complexes. Fig. S3 (E 
and F) shows tau uptake assays with N2a neuroblastoma cells 
and primary cortical neuronal cultures, demonstrating signifi-
cantly lower tau uptake in the presence of either SC1 or SC3 
scFvs. Fig. S3 G depicts data from a seeding assay, showing that 
immunodepletion with SC1 or SC3 scFvs inhibits seeding 
activity of P301S-tg brain lysates.
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Figure S1. all 9-mo-old mice express the scFvs. (A–C) Immunoblot analysis shows expression of SC1 (A; n = 14), SC3 (B; n = 16), and control (C; n = 
17) scFv in cortex samples of all 9-mo-old P301S-tg mice analyzed in the study. (D) ELI SA for unbound scFvs revealed similar scFv levels in hippocampal RAB 
fractions (n = 14 for SC1 scFv and n = 16 for SC3 scFv). (E) ELI SA for tau-scFv complexes detected complexes in hippocampal RAB fractions for all 9-mo-old 
P301S-tg mice except for lysates from two AAV2/8 SC3 scFv–injected mice that were below the detection limit of the assay (n = 14 for SC1 scFv and n = 16 
for SC3 scFv). All graphs represent means ± SEM.
Anti-tau scFvs decrease tau accumulation in vivo | Ising et al.S14
Figure S2. at8 staining correlates with salt-soluble and insoluble tau levels. (A–C) Correlation analysis across all groups showed a highly significant 
negative correlation between htau levels in RAB fractions and positive AT8 staining in the hippocampus (A), whereas there was a positive correlation for 
htau levels in FA fractions (C) and no correlation at all for htau levels in RIPA fractions (B; n = 45 in each analysis; 9-mo-old P301S-tg mice). Dashed lines 
represent 95% confidence intervals.
S15JEM
Figure S3. ScFvs bind to extracellular htau and inhibit tau uptake and seeding. (A) In vivo brain microdialysis followed by ELI SA showed no sig-
nificant differences (measured by one-way ANO VA) of extracellular htau levels between treatment groups in young (3–4.5 mo old) P301S-tg mice despite 
a trend to lower tau in SC3 scFv–treated mice (n = 9 for control scFv, n = 7 for SC1 scFv, and n = 8 for SC3 scFv; ISF collected at a flow rate of 1 µl/min). 
(B) Analysis of SC1 scFv– and SC3 scFv–treated mice showed a significant correlation between CSF and ISF htau levels in young P301S-tg mice (n = 6 for 
SC1 scFv and n = 8 for SC3 scFv). (C) No correlation between CSF and ISF htau levels was observed in young control scFv–treated P301S-tg mice (n = 8 for 
control scFv). (D) Coimmunoprecipitation from ISF samples (collected at a flow rate of 0.5 µl/min) with the anti-tau antibody HJ8.7 revealed coprecipitation 
of SC3 scFv with tau when analyzed by immunoblot. As a control, ISF sample buffer was mixed with the same concentration of purified SC3 scFv (n = 3). 
(E) Fluorescently labeled tau uptake by N2a cells measured by flow cytometry revealed the potential of SC1 and SC3 scFv to block cellular uptake (n = 7). 
(F) Fluorescently labeled tau uptake by primary cortical neuronal cultures measured by flow cytometry showed a significant inhibition of tau uptake in 
the presence of SC1 or SC3 scFvs (n = 4). (G) Immunodepletion with SC1 or SC3 scFvs inhibits seeding activity of P301S-tg brain lysate when analyzed by 
measuring the FRET signal in the biosensor cells (n = 3). Dashed lines in B and C represent 95% confidence intervals. All graphs are means ± SEM. A and 
E–G were analyzed by one-way ANO VA, followed by Dunnett’s multiple comparison post hoc test comparing every column to control scFv/untreated: *, P 
< 0.05; ***, P < 0.001.
